1. SIGLEC10 + macrophages drive gastric cancer progression by suppressing CD8 + T cell function.
- Author
-
Guo Y, Ke S, Xie F, Chen J, Liu X, Wang Z, Xu D, Shen Y, Zhao G, Zhao W, and Lu H
- Subjects
- Humans, CD8-Positive T-Lymphocytes, Macrophages, Prognosis, Immunotherapy, Tumor Microenvironment, Receptors, Cell Surface metabolism, Lectins metabolism, Stomach Neoplasms
- Abstract
Existing immune checkpoint inhibitors focus on activating T cells and show limited effectiveness in gastric cancer (GC). SIGLEC10 is identified as a novel tumor-associated macrophage-related immune checkpoint in other cancer types. However, its immunosuppressive role and clinical significance in GC remain unclear. In this study, we find a dominant expression of SIGLEC10 on CD68
+ macrophages in GC. SIGLEC10 can suppress the proliferation and function of tumor-infiltrating CD8+ T cells in vitro via the Akt/P38/Erk signaling pathway. Furthermore, in ex vivo and in vivo models, SIGLEC10 blockade promotes CD8+ T cell effector function. Finally, SIGLEC10+ macrophages are positively correlated with the adverse prognosis of GC. Our study highlights that SIGLEC10 directly suppresses T cell function and serves as a promising target for immunotherapy and suggests SIGLEC10+ macrophages as a novel potential predictor of the clinical prognosis of GC., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF